USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
US Oncology Diagnostics Market, Forecast to 2021
Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection
RELEASE DATE
17-Jul-2017
17-Jul-2017
REGION
North America
North America
DELIVERABLE TYPE
Market Research
Market Research
RESEARCH CODE
K165-01-00-00-00
K165-01-00-00-00
SKU
LS00273-NA-MR_20424
LS00273-NA-MR_20424
Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories.
Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes.
Important market opportunities that are predicted with high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States.
The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung.
Research highlights:
- Annual biopsies and projection estimates for all the cancer types (2016–2021)
- Revenue forecast by technology type (molecular vs non-molecular) and by intended use (screening, prognosis, diagnosis, therapy selection, and therapy monitoring/management)
- Key trends and growth opportunities
- Game-changing companies
- Disruptive technologies and business models
- Emerging biomarkers and companion diagnostic development landscape
- Pricing analysis
- Epidemiology studies for all cancer types (2016–2021)
- Strategic recommendations and future outlook of cancer market
Key issues addressed:
- Which are the cancer types that hold the highest potential in terms of revenue and growth?
- What are the tests and technologies used to screen, diagnose, and predict therapy in each of the cancers? Where are the new developments taking place?
- What does the current and prospective competitive landscape look like? What are the approaches being taken by participants to counter competitive threats?
- How is the landscape for mergers, acquisitions, and collaborations?
- What are the emerging biomarker opportunities for breast, prostate, cervical, ovarian, lung, and colorectal cancer for developing new tests?
- Which are the companies that are driving innovation within each cancer type?
Market Highlights
Scope and Segmentation
Top Economic Motivators for Cancer Testing
Trends Driving Cancer Testing
Examples of Competitive Developments
Future Trends—3 Big Predictions
Trends/Factors Impacting the Cancer Diagnostics Market
Cancer Market Trends
Market Drivers
Market Restraints
Notable Activities
Top Predictions for the Cancer Diagnostics Market
Objectives—Cancer Moonshot Program
Opportunities—Cancer Moonshot Program
Liquid Biopsy Technology—Investments
Competitor Matrix
Competitor Matrix—Technology Used
Revenue Forecast
Percent Revenue Forecast by Cancer Segment
Revenue Forecast by Cancer Segment
Total Biopsy Volume Snap Shot
Breast Cancer—Segmentation
Breast Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch
Companion Diagnostics—Strategy and Partnerships
Emerging Biomarkers
Summary of Therapeutic Pipeline with Companion Biomarker by Cancer Type
Summary of Therapeutic Pipeline by Phase
Summary of Therapeutic Targets
Summary of Therapeutic Pipeline with Companion Biomarker by Tumor Type
Summary of Tumor Types with Targeted Therapeutics
Companion Diagnostic Targets by Company
Companion Diagnostic Partnerships
Approved Companion Diagnostic Tests—United States
Keys Factors for Success in Cancer Diagnostic Space
Future Outlook and Emerging Opportunities
List of Abbreviations
Breast Cancer Epidemiology
Breast Cancer—US Incidence and Forecast, 2016–2021
Breast Cancer—Biomarkers and Assays
Ovarian Cancer Epidemiology
Ovarian Cancer—US Incidence and Forecast, 2016–2021
Ovarian Cancer—Biomarkers and Assays
Cervical Cancer Epidemiology
Cervical Cancer—US Incidence and Forecast, 2016–2021
Cervical Cancer—Biomarkers and Assays
Colorectal Cancer Epidemiology
Colorectal Cancer—US Incidence and Forecast, 2016–2021
Colorectal Cancer—Biomarkers and Assays
Prostate Cancer Epidemiology
Prostate Cancer—US Incidence and Forecast, 2016–2021
Prostate Cancer—Biomarkers and Assays
Lung Cancer Epidemiology
Lung Cancer—US Incidence and Forecast, 2016–2021
Lung Cancer—Biomarkers and Assays
Companies Represented in the Samples Studied
Legal Disclaimer
List of Figures
- 1. Total Oncology Diagnostics Market: Key Market Drivers, US, 2017–2021
- 2. Total Oncology Diagnostics Market: Key Market Restraints, US, 2017–2021
- 3. Total Oncology Diagnostics Market: Competitor Matrix, US, 2016
- 4. Total Oncology Diagnostics Market: Competitor Matrix, US, 2016
- 5. Total Oncology Diagnostics Market: Revenue Forecast by Cancer Segment, US, 2016–2021
- 6. Total Oncology Diagnostics Market: Biopsy Volume Forecast, US, 2015–2021
- 7. Oncology Diagnostics Market: Breast Cancer—Company Market Share Analysis of Top 4 Participants, US, 2016
- 8. Oncology Diagnostics Market: Pace of Breast Cancer Companion Diagnostics FDA Approvals, US, 1997–2016
- 9. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 1997–2016
- 10. Oncology Diagnostics Market: Emerging Biomarkers for Breast Cancer, US, 2017
- 11. Oncology Diagnostics Market: Ovarian Cancer—Company Market Share Analysis of Top 5 Participants, US, 2016
- 12. Oncology Diagnostics Market: Pace of Ovarian Cancer Companion Diagnostics FDA Approvals, US, 2013–2016
- 13. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2014–2016
- 14. Oncology Diagnostics Market: Cervical Cancer—Company Market Share Analysis of 3 Participants, US, 2016
- 15. Oncology Diagnostics Market: Colorectal Cancer—Company Market Share Analysis of Top 5 Participants, US, 2016
- 16. Oncology Diagnostics Market: Pace of Colorectal Cancer Companion Diagnostics FDA Approvals, US, 2004–2016
- 17. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2004–2015
- 18. Oncology Diagnostics Market: Prostate Cancer—Company Market Share Analysis of Top 4 Participants, US, 2016
- 19. Oncology Diagnostics Market: Lung Cancer—Company Market Share Analysis of Top 3 Participants, US, 2016
- 20. Oncology Diagnostics Market: Pace of Lung Cancer Companion Diagnostics FDA Approvals, US, 2011–2016
- 21. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2011–2016
- 22. Oncology Diagnostics Market: Pipeline of Cancer Biomarkers by Cancer Type, US, 2017
- 23. Companion Diagnostics Market: Top Cancers with Targeted Therapies, US, 2017
- 24. Oncology Diagnostics Market: Breast Cancer Epidemiology, US, 2016–2021
- 25. Oncology Diagnostics Market: Ovarian Cancer Epidemiology, US, 2016–2021
- 26. Oncology Diagnostics Market: Cervical Cancer Epidemiology, US, 2016–2021
- 27. Oncology Diagnostics Market: Colorectal Cancer Epidemiology, US, 2016–2021
- 28. Oncology Diagnostics Market: Prostate Cancer Epidemiology, US, 2016–2021
- 29. Oncology Diagnostics Market: Lung Cancer Epidemiology, US, 2016–2021
List of Charts
- 1. Total Oncology Diagnostics Market: Trends Driving Cancer Testing, US, 2016–2021
- 2. Total Oncology Diagnostics Market: Notable Mergers and Acquisitions, US, 2015 and 2016
- 3. Total Oncology Diagnostics Market: Notable Mergers and Acquisitions, US, 2016–2017
- 4. Total Oncology Diagnostics Market: Number of Companies Represented, US, 2016
- 5. Total Oncology Diagnostics Market: Revenue Forecast, US, 2016–2021
- 6. Total Oncology Diagnostics Market: Percent Revenue Forecast by Cancer Segment, US, 2016 and 2021
- 7. Oncology Diagnostics Market: Breast Cancer by Technology, US, 2016
- 8. Oncology Diagnostics Market: Breast Cancer by Function, US, 2016
- 9. Oncology Diagnostics Market: Breast Cancer Biopsy Volume, US, 2015–2021
- 10. Oncology Diagnostics Market: Opportunities for Breast Cancer Market, US, 2016 and 2021
- 11. Oncology Diagnostics Market: Breast Cancer Revenue Forecast by Technology, US, 2016–2021
- 12. Oncology Diagnostics Market: Breast Cancer Revenue Forecast by Function, US, 2016–2021
- 13. Oncology Diagnostics Market: Breast Cancer Market Share, US, 2016
- 14. Oncology Diagnostics Market: Ovarian Cancer Market by Technology, US, 2016
- 15. Oncology Diagnostics Market: Ovarian Cancer Market by Function, US, 2016
- 16. Oncology Diagnostics Market: Ovarian Cancer Biopsy Volume, US, 2015–2021
- 17. Oncology Diagnostics Market: Opportunities for Ovarian Cancer Market, US, 2016 and 2021
- 18. Oncology Diagnostics Market: Ovarian Cancer Revenue Forecast by Technology, US, 2016–2021
- 19. Oncology Diagnostics Market: Ovarian Cancer Revenue Forecast by Function, US, 2016–2021
- 20. Oncology Diagnostics Market: Ovarian Cancer Market Share, US, 2016
- 21. Oncology Diagnostics Market: Cervical Cancer by Technology, US, 2016
- 22. Oncology Diagnostics Market: Cervical Cancer by Function, US, 2016
- 23. Oncology Diagnostics Market: Cervical Cancer Biopsy Volume, US, 2015–2021
- 24. Oncology Diagnostics Market: Opportunities for Cervical Cancer Market, US, 2016 and 2021
- 25. Oncology Diagnostics Market: Cervical Cancer Revenue Forecast by Technology Type, US, 2016–2021
- 26. Oncology Diagnostics Market: Cervical Cancer Revenue Forecast by Function, US, 2016–2021
- 27. Oncology Diagnostics Market: Cervical Cancer Market Share, US, 2016
- 28. Oncology Diagnostics Market: Colorectal Cancer by Technology, US, 2016
- 29. Oncology Diagnostics Market: Colorectal Cancer by Function, US, 2016
- 30. Oncology Diagnostics Market: Colorectal Cancer Biopsy Volume, US, 2015–2021
- 31. Oncology Diagnostics Market: Opportunities for Colorectal Cancer Market, US, 2016 and 2021
- 32. Oncology Diagnostics Market: Colorectal Cancer Forecast by Technology, US, 2016–2021
- 33. Oncology Diagnostics Market: Colorectal Cancer Revenue Forecast by Function, US, 2016–2021
- 34. Oncology Diagnostics Market: Colorectal Cancer Market Share Analysis, US, 2016
- 35. Oncology Diagnostics Market: Prostate Cancer by Technology, US, 2016
- 36. Oncology Diagnostics Market: Prostate Cancer by Function, US, 2016
- 37. Oncology Diagnostics Market: Prostate Cancer Biopsy Volume, US, 2015–2021
- 38. Oncology Diagnostics Market: Opportunities for Prostate Cancer Market, US, 2016 and 2021
- 39. Oncology Diagnostics Market: Prostate Cancer Revenue Forecast by Technology, US, 2016–2021
- 40. Oncology Diagnostics Market: Prostate Cancer Revenue Forecast by Function, US, 2016–2021
- 41. Oncology Diagnostics Market: Prostate Cancer Market Share Analysis, US, 2016
- 42. Oncology Diagnostics Market: Lung Cancer by Technology, US, 2016
- 43. Oncology Diagnostics Market: Lung Cancer by Function, US, 2016
- 44. Oncology Diagnostics Market: Lung Cancer Biopsy Volume, US, 2015–2021
- 45. Oncology Diagnostics Market: Opportunities for Lung Cancer, US, 2016 and 2021
- 46. Oncology Diagnostics Market: Lung Cancer Revenue Forecast by Technology, US, 2016–2021
- 47. Oncology Diagnostics: Lung Cancer Revenue Forecast by Function, US, 2016–2021
- 48. Oncology Diagnostics Market: Lung Cancer Market Share Analysis, US, 2016
- 49. Oncology Diagnostics Market: Development Phases of Companion Products, US, 2016
- 50. Oncology Diagnostics Market: Drug Diagnostic Biomarker Targets, US, 2016
- 51. Oncology Diagnostics Market: Selected Solid Tumors, US, 2016
- 52. Oncology Diagnostics Market: Companion Dx Major Partnerships, US, 2017
- 53. Oncology Diagnostics Market: Breast Cancer Biomarkers by Function, US, 2017
- 54. Oncology Diagnostics Market: Ovarian Cancer Biomarkers by Function, US, 2017
- 55. Oncology Diagnostics Market: Cervical Cancer Biomarkers by Function, US, 2017
- 56. Oncology Diagnostics Market: Colorectal Cancer Biomarkers by Function, US, 2017
- 57. Oncology Diagnostics Market: Prostate Cancer Biomarkers by Function, US, 2017
- 58. Oncology Diagnostics Market: Lung Cancer Biomarkers by Function, US, 2017
Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories.
Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes.
Important market opportunities that are predicted with high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States.
The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung.
Highlights of the report include:
• Annual biopsies and projection estimates for all the cancer types (2016–2021)
• Revenue forecast by technology type (molecular vs non-molecular) and by intended use (screening, prognosis, diagnosis, therapy selection, and therapy monitoring/management)
• Key trends and growth opportunities
• Game-changing companies
• Disruptive techn
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Table of Contents | | Executive Summary~ || Market Highlights ~ || Scope and Segmentation~ || Top Economic Motivators for Cancer Testing~ || Trends Driving Cancer Testing~ || Examples of Competitive Developments~ || Future Trends—3 Big Predictions~ | US Oncology Diagnostics Market Overview~ || Trends/Factors Impacting the Cancer Diagnostics Market~ || Cancer Market Trends~ || Market Drivers~ || Market Restraints~ || Notable Activities~ || Top Predictions for the Cancer Diagnostics Market~ || Objectives—Cancer Moonshot Program~ || Opportunities—Cancer Moonshot Program~ || Liquid Biopsy Technology—Investments~ | Overview of Competitors~ || Competitor Matrix~ || Competitor Matrix—Technology Used~ | Total Cancer Diagnostics Market~ || Revenue Forecast~ || Percent Revenue Forecast by Cancer Segment~ || Revenue Forecast by Cancer Segment~ || Total Biopsy Volume Snap Shot~ | Breast Cancer~ || Breast Cancer—Segmentation~ || Breast Cancer Incidence and Estimated Biopsies~ || Growth Opportunities for Technology Providers~ || Pricing Analysis by Technology Format~ || Revenue Forecast by Technology Type~ || Revenue Forecast by Function~ || Market Share~ || Market Share Analysis~ || Key Companies to Watch~ || Companion Diagnostics—Strategy and Partnerships~ || Emerging Biomarkers~ | Ovarian Cancer~ | Cervical Cancer~ | Colorectal Cancer~ | Prostate Cancer~ | Lung Cancer~ | Companion Biomarker Opportunities in Drug Development~ || Summary of Therapeutic Pipeline with Companion Biomarker by Cancer Type~ || Summary of Therapeutic Pipeline by Phase ~ || Summary of Therapeutic Targets~ || Summary of Therapeutic Pipeline with Companion Biomarker by Tumor Type~ || Summary of Tumor Types with Targeted Therapeutics~ || Companion Diagnostic Targets by Company~ || Companion Diagnostic Partnerships~ || Approved Companion Diagnostic Tests—United States~ | Future Outlook and Emerging Opportunities~ || Keys Factors for Success in Cancer Diagnostic Space~ || Future Outlook and Emerging Opportunities~ | Appendix~ || List of Abbreviations~ || Breast Cancer Epidemiology~ || Breast Cancer—US Incidence and Forecast, 2016–2021~ || Breast Cancer—Biomarkers and Assays~ || Ovarian Cancer Epidemiology~ || Ovarian Cancer—US Incidence and Forecast, 2016–2021~ || Ovarian Cancer—Biomarkers and Assays~ || Cervical Cancer Epidemiology~ || Cervical Cancer—US Incidence and Forecast, 2016–2021~ || Cervical Cancer—Biomarkers and Assays~ || Colorectal Cancer Epidemiology~ || Colorectal Cancer—US Incidence and Forecast, 2016–2021~ || Colorectal Cancer—Biomarkers and Assays~ || Prostate Cancer Epidemiology~ || Prostate Cancer—US Incidence and Forecast, 2016–2021~ || Prostate Cancer—Biomarkers and Assays~ || Lung Cancer Epidemiology~ || Lung Cancer—US Incidence and Forecast, 2016–2021~ || Lung Cancer—Biomarkers and Assays~ || Companies Represented in the Samples Studied~ || Legal Disclaimer~ | The Frost & Sullivan Story~ |
| List of Charts and Figures | 1. Total Oncology Diagnostics Market: Key Market Drivers, US, 2017–2021~ 2. Total Oncology Diagnostics Market: Key Market Restraints, US, 2017–2021~ 3. Total Oncology Diagnostics Market: Competitor Matrix, US, 2016~ 4. Total Oncology Diagnostics Market: Competitor Matrix, US, 2016~ 5. Total Oncology Diagnostics Market: Revenue Forecast by Cancer Segment, US, 2016–2021~ 6. Total Oncology Diagnostics Market: Biopsy Volume Forecast, US, 2015–2021~ 7. Oncology Diagnostics Market: Breast Cancer—Company Market Share Analysis of Top 4 Participants, US, 2016~ 8. Oncology Diagnostics Market: Pace of Breast Cancer Companion Diagnostics FDA Approvals, US, 1997–2016~ 9. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 1997–2016~ 10. Oncology Diagnostics Market: Emerging Biomarkers for Breast Cancer, US, 2017~ 11. Oncology Diagnostics Market: Ovarian Cancer—Company Market Share Analysis of Top 5 Participants, US, 2016~ 12. Oncology Diagnostics Market: Pace of Ovarian Cancer Companion Diagnostics FDA Approvals, US, 2013–2016~ 13. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2014–2016~ 14. Oncology Diagnostics Market: Cervical Cancer—Company Market Share Analysis of 3 Participants, US, 2016~ 15. Oncology Diagnostics Market: Colorectal Cancer—Company Market Share Analysis of Top 5 Participants, US, 2016~ 16. Oncology Diagnostics Market: Pace of Colorectal Cancer Companion Diagnostics FDA Approvals, US, 2004–2016~ 17. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2004–2015~ 18. Oncology Diagnostics Market: Prostate Cancer—Company Market Share Analysis of Top 4 Participants, US, 2016~ 19. Oncology Diagnostics Market: Lung Cancer—Company Market Share Analysis of Top 3 Participants, US, 2016~ 20. Oncology Diagnostics Market: Pace of Lung Cancer Companion Diagnostics FDA Approvals, US, 2011–2016~ 21. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2011–2016~ 22. Oncology Diagnostics Market: Pipeline of Cancer Biomarkers by Cancer Type, US, 2017~ 23. Companion Diagnostics Market: Top Cancers with Targeted Therapies, US, 2017~ 24. Oncology Diagnostics Market: Breast Cancer Epidemiology, US, 2016–2021~ 25. Oncology Diagnostics Market: Ovarian Cancer Epidemiology, US, 2016–2021~ 26. Oncology Diagnostics Market: Cervical Cancer Epidemiology, US, 2016–2021~ 27. Oncology Diagnostics Market: Colorectal Cancer Epidemiology, US, 2016–2021~ 28. Oncology Diagnostics Market: Prostate Cancer Epidemiology, US, 2016–2021~ 29. Oncology Diagnostics Market: Lung Cancer Epidemiology, US, 2016–2021~| 1. Total Oncology Diagnostics Market: Trends Driving Cancer Testing, US, 2016–2021~ 2. Total Oncology Diagnostics Market: Notable Mergers and Acquisitions, US, 2015 and 2016~ 3. Total Oncology Diagnostics Market: Notable Mergers and Acquisitions, US, 2016–2017~ 4. Total Oncology Diagnostics Market: Number of Companies Represented, US, 2016~ 5. Total Oncology Diagnostics Market: Revenue Forecast, US, 2016–2021~ 6. Total Oncology Diagnostics Market: Percent Revenue Forecast by Cancer Segment, US, 2016 and 2021~ 7. Oncology Diagnostics Market: Breast Cancer by Technology, US, 2016~ 8. Oncology Diagnostics Market: Breast Cancer by Function, US, 2016~ 9. Oncology Diagnostics Market: Breast Cancer Biopsy Volume, US, 2015–2021~ 10. Oncology Diagnostics Market: Opportunities for Breast Cancer Market, US, 2016 and 2021~ 11. Oncology Diagnostics Market: Breast Cancer Revenue Forecast by Technology, US, 2016–2021~ 12. Oncology Diagnostics Market: Breast Cancer Revenue Forecast by Function, US, 2016–2021~ 13. Oncology Diagnostics Market: Breast Cancer Market Share, US, 2016~ 14. Oncology Diagnostics Market: Ovarian Cancer Market by Technology, US, 2016~ 15. Oncology Diagnostics Market: Ovarian Cancer Market by Function, US, 2016~ 16. Oncology Diagnostics Market: Ovarian Cancer Biopsy Volume, US, 2015–2021~ 17. Oncology Diagnostics Market: Opportunities for Ovarian Cancer Market, US, 2016 and 2021~ 18. Oncology Diagnostics Market: Ovarian Cancer Revenue Forecast by Technology, US, 2016–2021~ 19. Oncology Diagnostics Market: Ovarian Cancer Revenue Forecast by Function, US, 2016–2021~ 20. Oncology Diagnostics Market: Ovarian Cancer Market Share, US, 2016~ 21. Oncology Diagnostics Market: Cervical Cancer by Technology, US, 2016 ~ 22. Oncology Diagnostics Market: Cervical Cancer by Function, US, 2016~ 23. Oncology Diagnostics Market: Cervical Cancer Biopsy Volume, US, 2015–2021~ 24. Oncology Diagnostics Market: Opportunities for Cervical Cancer Market, US, 2016 and 2021~ 25. Oncology Diagnostics Market: Cervical Cancer Revenue Forecast by Technology Type, US, 2016–2021~ 26. Oncology Diagnostics Market: Cervical Cancer Revenue Forecast by Function, US, 2016–2021~ 27. Oncology Diagnostics Market: Cervical Cancer Market Share, US, 2016~ 28. Oncology Diagnostics Market: Colorectal Cancer by Technology, US, 2016~ 29. Oncology Diagnostics Market: Colorectal Cancer by Function, US, 2016~ 30. Oncology Diagnostics Market: Colorectal Cancer Biopsy Volume, US, 2015–2021~ 31. Oncology Diagnostics Market: Opportunities for Colorectal Cancer Market, US, 2016 and 2021~ 32. Oncology Diagnostics Market: Colorectal Cancer Forecast by Technology, US, 2016–2021~ 33. Oncology Diagnostics Market: Colorectal Cancer Revenue Forecast by Function, US, 2016–2021~ 34. Oncology Diagnostics Market: Colorectal Cancer Market Share Analysis, US, 2016~ 35. Oncology Diagnostics Market: Prostate Cancer by Technology, US, 2016~ 36. Oncology Diagnostics Market: Prostate Cancer by Function, US, 2016~ 37. Oncology Diagnostics Market: Prostate Cancer Biopsy Volume, US, 2015–2021~ 38. Oncology Diagnostics Market: Opportunities for Prostate Cancer Market, US, 2016 and 2021~ 39. Oncology Diagnostics Market: Prostate Cancer Revenue Forecast by Technology, US, 2016–2021~ 40. Oncology Diagnostics Market: Prostate Cancer Revenue Forecast by Function, US, 2016–2021~ 41. Oncology Diagnostics Market: Prostate Cancer Market Share Analysis, US, 2016~ 42. Oncology Diagnostics Market: Lung Cancer by Technology, US, 2016~ 43. Oncology Diagnostics Market: Lung Cancer by Function, US, 2016~ 44. Oncology Diagnostics Market: Lung Cancer Biopsy Volume, US, 2015–2021~ 45. Oncology Diagnostics Market: Opportunities for Lung Cancer, US, 2016 and 2021~ 46. Oncology Diagnostics Market: Lung Cancer Revenue Forecast by Technology, US, 2016–2021~ 47. Oncology Diagnostics: Lung Cancer Revenue Forecast by Function, US, 2016–2021~ 48. Oncology Diagnostics Market: Lung Cancer Market Share Analysis, US, 2016~ 49. Oncology Diagnostics Market: Development Phases of Companion Products, US, 2016~ 50. Oncology Diagnostics Market: Drug Diagnostic Biomarker Targets, US, 2016~ 51. Oncology Diagnostics Market: Selected Solid Tumors, US, 2016~ 52. Oncology Diagnostics Market: Companion Dx Major Partnerships, US, 2017~ 53. Oncology Diagnostics Market: Breast Cancer Biomarkers by Function, US, 2017~ 54. Oncology Diagnostics Market: Ovarian Cancer Biomarkers by Function, US, 2017~ 55. Oncology Diagnostics Market: Cervical Cancer Biomarkers by Function, US, 2017~ 56. Oncology Diagnostics Market: Colorectal Cancer Biomarkers by Function, US, 2017~ 57. Oncology Diagnostics Market: Prostate Cancer Biomarkers by Function, US, 2017~ 58. Oncology Diagnostics Market: Lung Cancer Biomarkers by Function, US, 2017~ |
| Lightbox Content | World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019 |
| Author | Divyaa Ravishankar |
| WIP Number | K165-01-00-00-00 |
| Is Prebook | No |
US Oncology Diagnostics Market, Forecast to 2021
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
LS00273-NA-MR_20424